KR20210114946A - 뇌성마비에서의 운동이상증의 치료를 위한 듀테트라베나진 - Google Patents
뇌성마비에서의 운동이상증의 치료를 위한 듀테트라베나진 Download PDFInfo
- Publication number
- KR20210114946A KR20210114946A KR1020217021438A KR20217021438A KR20210114946A KR 20210114946 A KR20210114946 A KR 20210114946A KR 1020217021438 A KR1020217021438 A KR 1020217021438A KR 20217021438 A KR20217021438 A KR 20217021438A KR 20210114946 A KR20210114946 A KR 20210114946A
- Authority
- KR
- South Korea
- Prior art keywords
- patient
- baseline
- deuterabenazine
- score
- study
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862779232P | 2018-12-13 | 2018-12-13 | |
| US62/779,232 | 2018-12-13 | ||
| US201962801450P | 2019-02-05 | 2019-02-05 | |
| US62/801,450 | 2019-02-05 | ||
| PCT/US2019/066150 WO2020123900A1 (en) | 2018-12-13 | 2019-12-13 | Deutetrabenazine for the treatment of dyskinesia in cerebral palsy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20210114946A true KR20210114946A (ko) | 2021-09-24 |
Family
ID=69173404
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217021438A Abandoned KR20210114946A (ko) | 2018-12-13 | 2019-12-13 | 뇌성마비에서의 운동이상증의 치료를 위한 듀테트라베나진 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US11324732B2 (https=) |
| EP (1) | EP3893876A1 (https=) |
| JP (1) | JP2022519007A (https=) |
| KR (1) | KR20210114946A (https=) |
| CN (1) | CN113395966A (https=) |
| AU (1) | AU2019395250A1 (https=) |
| BR (1) | BR112021011386A2 (https=) |
| CA (1) | CA3123393A1 (https=) |
| CL (1) | CL2021001554A1 (https=) |
| IL (1) | IL283920A (https=) |
| MX (1) | MX2021007063A (https=) |
| SG (1) | SG11202106344SA (https=) |
| TW (1) | TWI784220B (https=) |
| WO (1) | WO2020123900A1 (https=) |
| ZA (1) | ZA202104786B (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240058028A (ko) | 2022-10-24 | 2024-05-03 | 주식회사 디자인셀 | 줄기세포 배양액 및 상기로부터 분리된 세포외소포를 유효성분으로 포함하는 뇌신경계 질환의 예방 또는 치료용 약학적 조성물 |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210114946A (ko) * | 2018-12-13 | 2021-09-24 | 오스펙스 파마슈티칼스, 인코포레이티드 | 뇌성마비에서의 운동이상증의 치료를 위한 듀테트라베나진 |
| BR112023021257A2 (pt) * | 2021-04-15 | 2023-12-12 | Neurocrine Biosciences Inc | Métodos para a administração combinada de deutetrabenzina e um cyp2d6 |
| WO2022221551A1 (en) * | 2021-04-15 | 2022-10-20 | Neurocrine Biosciences, Inc. | Methods for the administration of certain vmat2 inhibitors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2972242A1 (en) * | 2008-09-18 | 2010-04-22 | Auspex Pharmaceuticals, Inc. | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| AU2015200243B2 (en) * | 2009-06-24 | 2016-09-29 | Egalet Ltd | Controlled release formulations |
| EP3351247A1 (en) * | 2010-06-01 | 2018-07-25 | Auspex Pharmaceutical, Inc. | Benzoquinolone inhibitors of vmat2 |
| EP4345100A3 (en) | 2012-09-18 | 2024-04-10 | Auspex Pharmaceuticals, Inc. | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| AU2016229949B2 (en) | 2015-03-06 | 2021-04-08 | Auspex Pharmaceuticals Llc | Methods for the treatment of abnormal involuntary movement disorders |
| PE20191819A1 (es) | 2017-03-15 | 2019-12-27 | Auspex Pharmaceuticals Inc | Analogos de deutetrabenazina, su preparacion y uso |
| KR20210114946A (ko) * | 2018-12-13 | 2021-09-24 | 오스펙스 파마슈티칼스, 인코포레이티드 | 뇌성마비에서의 운동이상증의 치료를 위한 듀테트라베나진 |
-
2019
- 2019-12-13 KR KR1020217021438A patent/KR20210114946A/ko not_active Abandoned
- 2019-12-13 JP JP2021534126A patent/JP2022519007A/ja active Pending
- 2019-12-13 WO PCT/US2019/066150 patent/WO2020123900A1/en not_active Ceased
- 2019-12-13 MX MX2021007063A patent/MX2021007063A/es unknown
- 2019-12-13 EP EP19839001.5A patent/EP3893876A1/en not_active Withdrawn
- 2019-12-13 TW TW108145866A patent/TWI784220B/zh active
- 2019-12-13 SG SG11202106344SA patent/SG11202106344SA/en unknown
- 2019-12-13 BR BR112021011386-0A patent/BR112021011386A2/pt not_active Application Discontinuation
- 2019-12-13 AU AU2019395250A patent/AU2019395250A1/en not_active Abandoned
- 2019-12-13 CN CN201980089635.4A patent/CN113395966A/zh active Pending
- 2019-12-13 CA CA3123393A patent/CA3123393A1/en active Pending
- 2019-12-13 US US16/713,917 patent/US11324732B2/en active Active
-
2021
- 2021-06-11 CL CL2021001554A patent/CL2021001554A1/es unknown
- 2021-06-12 IL IL283920A patent/IL283920A/en unknown
- 2021-07-08 ZA ZA2021/04786A patent/ZA202104786B/en unknown
-
2022
- 2022-04-12 US US17/718,441 patent/US20220409597A1/en not_active Abandoned
-
2023
- 2023-06-28 US US18/343,197 patent/US20240082225A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240058028A (ko) | 2022-10-24 | 2024-05-03 | 주식회사 디자인셀 | 줄기세포 배양액 및 상기로부터 분리된 세포외소포를 유효성분으로 포함하는 뇌신경계 질환의 예방 또는 치료용 약학적 조성물 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20200188371A1 (en) | 2020-06-18 |
| US20220409597A1 (en) | 2022-12-29 |
| CL2021001554A1 (es) | 2022-02-11 |
| WO2020123900A1 (en) | 2020-06-18 |
| EP3893876A1 (en) | 2021-10-20 |
| ZA202104786B (en) | 2023-12-20 |
| US20240082225A1 (en) | 2024-03-14 |
| CA3123393A1 (en) | 2020-06-18 |
| CN113395966A (zh) | 2021-09-14 |
| US11324732B2 (en) | 2022-05-10 |
| IL283920A (en) | 2021-07-29 |
| AU2019395250A1 (en) | 2021-07-29 |
| TWI784220B (zh) | 2022-11-21 |
| MX2021007063A (es) | 2021-12-10 |
| JP2022519007A (ja) | 2022-03-18 |
| TW202034917A (zh) | 2020-10-01 |
| BR112021011386A2 (pt) | 2021-08-31 |
| SG11202106344SA (en) | 2021-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250302851A1 (en) | Methods of treating neurocognitive disorders, chronic pain and reducing inflammation | |
| ES2879631T3 (es) | Pridopidina para el tratamiento de la enfermedad de Huntington | |
| Gaffney et al. | Risperidone versus clonidine in the treatment of children and adolescents with Tourette's syndrome | |
| US20240082225A1 (en) | Methods for the treatment of dyskinesia in cerebral palsy | |
| CN108135865A (zh) | 使用芬氟拉明治疗Lennox-Gastaut综合征的方法 | |
| US20230321007A1 (en) | Pharmacokinetics of nmda receptor antagonists | |
| US12390456B2 (en) | Pridopidine for treating Huntington's disease | |
| US20250352533A1 (en) | Pridopidine for treating huntington's disease | |
| EA012036B1 (ru) | Мемантин для лечения расстройств поведения детского возраста | |
| TW202102219A (zh) | 使用氘化右旋美沙芬(dextromethorphan)及奎尼丁(quinidine)治療精神分裂症之負面徵候之方法 | |
| CN118555956A (zh) | 用于治疗难治性抑郁症的赛洛西宾和辅助血清素再摄取抑制剂 | |
| JP2024517937A (ja) | Ｎｍｄａ受容体拮抗薬の副作用の低減 | |
| CN121013719A (zh) | 治疗特发性震颤的方法 | |
| JP2024525424A (ja) | 脳性麻痺によるジスキネジアの処置における使用のためのバルベナジン | |
| EA044015B1 (ru) | Дейтетрабеназин для лечения дискинезии при церебральном параличе | |
| US20250375417A1 (en) | Orexin receptor 2 (ox2r) agonist for use in narcolepsy type 1 (nt1) | |
| EP4618973A1 (en) | Methods of switching neuropsychiatric medications using ulotaront | |
| Adler et al. | Intervention Helps Workers With Depression. | |
| HK40060751A (en) | Methods of treating negative symptoms of schizophrenia using deuterated dextromethorphan and quinidine | |
| CA2764927A1 (en) | Exo-s-mecamylamine method, use, and compound for treatment | |
| BA | A randomized, placebo-controlled crossover trial of phentermine-topiramate ER in patients with binge-eating disorder and bulimia nervosa | |
| EA039995B1 (ru) | Применение придопидина для лечения болезни хантингтона |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20210708 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20221202 Comment text: Request for Examination of Application |
|
| PC1902 | Submission of document of abandonment before decision of registration |